Rhumbline Advisers Increases Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Rhumbline Advisers lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 146.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 270,941 shares of the biotechnology company’s stock after purchasing an additional 160,942 shares during the quarter. Rhumbline Advisers owned about 0.29% of Sarepta Therapeutics worth $42,809,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $26,000. Mather Group LLC. purchased a new position in Sarepta Therapeutics during the first quarter worth about $28,000. Riggs Asset Managment Co. Inc. boosted its stake in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the period. Innealta Capital LLC purchased a new position in Sarepta Therapeutics during the second quarter worth about $31,000. Finally, New Covenant Trust Company N.A. purchased a new position in Sarepta Therapeutics during the first quarter worth about $32,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on SRPT. Robert W. Baird increased their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, June 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $235.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, June 27th. Barclays lowered their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Morgan Stanley reissued an “overweight” rating and set a $165.00 price target on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, August 15th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $186.22.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $133.77 on Friday. The firm has a market capitalization of $12.64 billion, a P/E ratio of 1,216.09 and a beta of 0.89. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The firm’s 50 day moving average is $143.08 and its two-hundred day moving average is $133.15.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm’s revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.27) earnings per share. Research analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In other news, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The disclosure for this sale can be found here. Insiders have sold 52,801 shares of company stock worth $8,399,586 over the last three months. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.